Clues to Aging Found in Stem Cells’ Genomes

| February 22, 2018

article image
Stem cells that produce sperm use a genetic trick to stay perpetually young across generations, Howard Hughes Medical Institute (HHMI) Investigator Yukiko Yamashita and colleagues have discovered. Certain sections of the fruit fly genome get shorter with age. But remarkably, some reproductive cells can repair the shrinkage, Yamashita’s team reports February 13, 2018 in the journal eLife.

Spotlight

OncoDNA

OncoDNA’s aim is to provide medical innovations based on targeted sequencing or complete sequencing of tumour genomes, in order to assist medical doctors in their treatment choices and/or provide better monitoring of the evolution of patient tumors. The ambition of the newly created company is to “rapidly become a European reference for personalized analysis in oncology, based on the analysis of tumour’s DNA from patients.” said Jean-Pol Detiffe, founder and CEO of OncoDNA. “We will provide innovative analyses to private hospitals, research centres and also pharmaceutical clients”, he added.

OTHER ARTICLES

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

Defense biotech research looks to eliminate bacteria causing traveler’s diarrhea, reduce jet lag duration

Article | April 9, 2020

World traveler‘s will rejoice at the idea of a seemingly magical device that would guarantee they never suffer from the all-too-familiar stomach issues that come from traveling internationally while reducing jet lag at the same time. But it’s not just privileged globetrotters that would benefit from a device that eliminates the bacteria associated with the so-called Montezuma’s Revenge. In 2016, more than 230,000 children around the world died from some of the same types of bacteria as those that cause traveler’s diarrhea, and the bacteria mainly come from unsafe “drinking water, poor sanitation and malnutrition,” according to Oxford University’s Our World In Data portal. On Monday, DARPA announced it was researching an “implantable or ingestible bioelectronic carrier” that would eliminate the five major bacteria associated with traveler’s diarrhea.

Read More

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Ruminating on Bioprocessing 4.0

Article | February 18, 2020

The Bioprocessing 4.0 concept seeks to apply automation and technology to the digital transformation of biologics manufacturing. As the paradigm moves forward, it faces barriers to its adoption, according to Eric Langer, president of BioPlan Associates. “Perhaps the greatest challenges involve unsecured links and adapting the applications to areas where automation is critically needed today,” says Langer. “Unresolved security issues could seriously affect a company’s data in a regulated environment, so they will need to have iron-clad anti-hacking protection in place. Unfortunately, cyber security is not yet a top focus for the industry.”

Read More

Spotlight

OncoDNA

OncoDNA’s aim is to provide medical innovations based on targeted sequencing or complete sequencing of tumour genomes, in order to assist medical doctors in their treatment choices and/or provide better monitoring of the evolution of patient tumors. The ambition of the newly created company is to “rapidly become a European reference for personalized analysis in oncology, based on the analysis of tumour’s DNA from patients.” said Jean-Pol Detiffe, founder and CEO of OncoDNA. “We will provide innovative analyses to private hospitals, research centres and also pharmaceutical clients”, he added.

Events